710 West 168th StreetNew York, NY 10032
Overview of Dr. Lassman
Andrew Lassman, MD, is a New York-based neurologist specializing in neurooncology. He completed his fellowship in neuro-oncology at Memorial Sloan Kettering Cancer Center, his neurology residency at New York Presbyterian Hospital, and earned his MD from Columbia University Vagelos College of Physicians and Surgeons. Dr. Lassman is the Associate Dean of Clinical Trials and Division Chief at the same institution. His expertise includes glioblastoma, astrocytoma, oligodendroglioma, brain tumors, and meningiomas. He has published several research articles, including on gliomas and oncology treatment strategies, with notable citations. He is involved in clinical trials focusing on innovative treatments for glioblastoma and related malignancies. Dr. Lassman has been recognized as a top doctor by Castle Connolly and featured in New York Magazine.
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Neuro-Oncology, 2001 - 2003
New York Presbyterian Hospital (Columbia Campus)Residency, Neurology, 1998 - 2001
Icahn School of Medicine at Mount Sinai/Mount Sinai HospitalInternship, Internal Medicine, 1997 - 1998
Columbia University Vagelos College of Physicians and SurgeonsClass of 1997, MD
Certifications & Licensure
NJ State Medical License 2022 - 2027
NY State Medical License 1998 - 2027
CT State Medical License 2023 - 2026
KS State Medical License 2021 - 2026
American Board of Psychiatry and Neurology Neurology
Awards, Honors, & Recognition
- New York Magazine: Top Doctors Castle Connolly
- America's Top Doctors Castle Connolly
- Top Doctors: New York Metro Area Castle Connolly
Clinical Trials
- Dasatinib in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma Start of enrollment: 2007 Jan 24
- Temozolomide in Treating Patients With Recurrent Glioblastoma Multiforme or Other Malignant Glioma Start of enrollment: 2007 Jun 01
- Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma Start of enrollment: 2007 Oct 01
Publications & Presentations
PubMed
- Reply to: Blood-Brain Barrier Heterogeneity in NRG BN007: Implications for Immunotherapy Delivery.Andrew B Lassman, Mei-Yin C Polley, Fabio M Iwamoto, Vinai Gondi, Erik P Sulman
Journal of Clinical Oncology. 2026-01-16 - 1 citationsTherapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults: ASCO-SNO Guideline Rapid Recommendation Update Clinical Insights.Nimish A Mohile, Andrew B Lassman, David Schiff, Jaishri Blakeley
JCO Oncology Practice. 2026-01-01 - 1 citationsSTELLAR: Phase III, Randomized, Open-Label Study of Eflornithine Plus Lomustine Versus Lomustine Alone in Patients With Recurrent Grade 3 Astrocytoma.Howard Colman, Giuseppe Lombardi, Eric T Wong, Tobias Walbert, Marica Eoli
Journal of Clinical Oncology. 2025-12-01
Press Mentions
Combining Dual Immune Checkpoint Inhibition with Radiotherapy Fails to Enhance Progression-Free Survival in Newly Diagnosed MGMT-Unmethylated Glioblastoma PatientsAugust 13th, 2025- Brain Cancer: The Latest Advancements on Diagnostics, TreatmentOctober 25th, 2022
- Conversation with Anil K. Rustgi, MD, on Visit by Jill Biden and Queen of SpainSeptember 21st, 2022
Grant Support
- Clinical Trials Specialist in NCI Clinical Trials ResearchCOLUMBIA UNIVERSITY HEALTH SCIENCES2025–2030
Professional Memberships
- Member
Insurance Accepted
- Aetna Choice POS II
Aetna HMO
BCBS Blue Card PPO
BCBS Illinois PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Empire BCBS HMO
Empire BCBS PPO
GHI PPO
Great West PPOHealthfirst New York
HIP of New York - Select PPO
Humana ChoiceCare Network PPO
MVP Healthcare PPO
Oxford Health Freedom
Oxford Health Liberty
QualCare HMO
QualCare PPO
Sagamore Health Plus
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO - Please verify your coverage with the provider's office directly when scheduling an appointment
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
